<DOC>
	<DOCNO>NCT01382277</DOCNO>
	<brief_summary>This multicentre , open-label , single-arm Study evaluate effect Rosuvastatin 20 mg 76 week coronary atherosclerosis plaque versus baseline Chinese coronary heart disease ( CHD ) patient hyperlipidemia measure plaque volume use 64 slice spiral CT. Effect blood lipid , hsCRP Carotid intima-media thickness ( CIMT ) also evaluate .</brief_summary>
	<brief_title>Rosuvastatin Effect Reducing Coronary Atherosclerosis Plaques Volume</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Written inform consent Men woman , age 18 75 Diagnosed coronary heart disease ( CHD ) stable angina 1 month meet follow one : 1 . History myocardial infarction . 2 . CHD confirm coronary angiography . 3 . Excercise ECG positive CHD perfusion defect 4 . One main branch coronary artery stenosis ≥ 50 % confirm CT scan . Hyperlipidemia ( lipidlowering treatment naïve : LDLC ≥130mg/dl , receive lipidlowering treatment : LDLC ≥100mg/dl ) The 64 slice CT show least one significant coronary artery stenosis ≥20 % narrow ≤60 % meeting follow criterion : 1 . Diameter coronary artery lesion ≥2mm , length ≥5mm ; distance multiple lesion ＞1cm 2 . Plaque density ＜100HU , calcification 3 . Vascular stenosis ( 20～60 % ) cause plaque 4 . Plaque thickness ＞1mm 5 . Plaque coronary artery previous PCI treatment . Acute myocardial infarction within 6 month PCI CABG therapy within 6 month Anticipated PCI CABG therapy follow 3 month . Tropnin I/Tropnin T high ULN Cardiac failure NYHA III Coronary artery leave main stenosis &gt; 50 % Emergency coronary angiography ( CAG ) need Serious arrhythmia tachycardia Secondary hyperlipidemia Familial hypercholestrolemia Uncontrolled severe hypertension ( ≥200/110 mmHg ) Uncontrolled diabetes ( HbA1c ≥9.5 % ) Triglyceride ≥500 mg/dL ( 5.65 mmol/L ) Active hepatic disease hepatic function impairment , ALT≥3ULN Serum creatinine &gt; 177 µmol/L ( 2.0 mg/dL ) Myalgia blood CK ≥5ULN WBC &lt; 4×10e9/L，or PLT &lt; 100*10e9/L。 Participation course plan and/or procedure study Previous participation study treatment Participation clinical study past 3 month Pregnant breastfeed woman , woman childbearing potential use drug device contraception , woman positive urine pregnancy test ( human chorionic gonadotropin [ HCG ] ) History malignant tumor ( exception : recover 10 year basal cell carcinoma squamous cell carcinoma ) ; females history cervical atypical hyperplasia ( exception : 3 consecutive cervical smear test normal prior enrolment ) History alcohol and/or drug abuse recent 5 year Any serious unstable physical psychological condition , opinion investigator , would compromise safety patient participation study Use concomitant medication prohibit study ( Erythromycin , clarithromycin , erythromycin ethylsuccinate , sulfaphenazole ; Fluconazole , ketoconazole , itraconazole ; Niacin / nicotinic acid ( include vitamins/food additive contain niacin / nicotinic acid &gt; 50mg ) , probucol , clofibrate , cholestyramine , colestipol hydrochloride , ezetimibe , fenofibrate , gemfibrozil , atorvastatin ( exception : study medication ) ，lovastatin , pravastatin , rosuvastatin ( exception : study medication ) , Simvastatin , fluvastatin , fish oil ( dose ) , lipidlowering supplement food additive ; Cyclosporine ; Protease inhibitor ) Use periodic hormone replacement treatment ( HRT ) , oral contraceptive ( OCTs ) , longacting progesterone , recent 3 month nonperiodic HRT OCTs Patients condition , investigator 's judgment , might increase risk subject adverse event abnormal laboratory find</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2011</verification_date>
</DOC>